In a report released today, Michael Petusky from Barrington maintained a Buy rating on Lemaitre Vascular (LMAT), with a price target of $36.00. The company’s shares closed last Tuesday at $32.14.
According to TipRanks.com, Petusky is a 4-star analyst with an average return of 4.0% and a 48.6% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Varian Medical Systems, Merit Medical Systems, and US Physical Therapy.
Currently, the analyst consensus on Lemaitre Vascular is a Moderate Buy with an average price target of $33.20.
See today’s analyst top recommended stocks >>
The company has a one-year high of $38.64 and a one-year low of $18.76. Currently, Lemaitre Vascular has an average volume of 126.3K.
Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of LMAT in relation to earlier this year. Most recently, in July 2020, John James O’connor, a Director at LMAT bought 7,500 shares for a total of $85,725.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company focuses on the design, marketing, sales, service, and technical support of medical devices and implants for the treatment of peripheral vascular disease. Its products include balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy. The company was founded by George D. LeMaitre on November 28, 1983 and is headquartered in Burlington, MA.